1
|
Rikkert LG, Beekman P, Caro J, Coumans FAW, Enciso-Martinez A, Jenster G, Le Gac S, Lee W, van Leeuwen TG, Loozen GB, Nanou A, Nieuwland R, Offerhaus HL, Otto C, Pegtel DM, Piontek MC, van der Pol E, de Rond L, Roos WH, Schasfoort RBM, Wauben MHM, Zuilhof H, Terstappen LWMM. Cancer-ID: Toward Identification of Cancer by Tumor-Derived Extracellular Vesicles in Blood. Front Oncol 2020; 10:608. [PMID: 32582525 PMCID: PMC7287034 DOI: 10.3389/fonc.2020.00608] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2020] [Accepted: 04/02/2020] [Indexed: 12/19/2022] Open
Abstract
Extracellular vesicles (EVs) have great potential as biomarkers since their composition and concentration in biofluids are disease state dependent and their cargo can contain disease-related information. Large tumor-derived EVs (tdEVs, >1 μm) in blood from cancer patients are associated with poor outcome, and changes in their number can be used to monitor therapy effectiveness. Whereas, small tumor-derived EVs (<1 μm) are likely to outnumber their larger counterparts, thereby offering better statistical significance, identification and quantification of small tdEVs are more challenging. In the blood of cancer patients, a subpopulation of EVs originate from tumor cells, but these EVs are outnumbered by non-EV particles and EVs from other origin. In the Dutch NWO Perspectief Cancer-ID program, we developed and evaluated detection and characterization techniques to distinguish EVs from non-EV particles and other EVs. Despite low signal amplitudes, we identified characteristics of these small tdEVs that may enable the enumeration of small tdEVs and extract relevant information. The insights obtained from Cancer-ID can help to explore the full potential of tdEVs in the clinic.
Collapse
Affiliation(s)
- L G Rikkert
- Department of Medical Cell Biophysics, University of Twente, Enschede, Netherlands.,Laboratory of Experimental Clinical Chemistry, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.,Vesicle Observation Center, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | - P Beekman
- Department of Medical Cell Biophysics, University of Twente, Enschede, Netherlands.,Laboratory of Organic Chemistry, Wageningen University, Wageningen, Netherlands.,Applied Microfluidics for Bioengineering Research, University of Twente, Enschede, Netherlands
| | - J Caro
- Department of Imaging Physics, Delft University of Technology, Delft, Netherlands
| | - F A W Coumans
- Laboratory of Experimental Clinical Chemistry, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.,Vesicle Observation Center, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | - A Enciso-Martinez
- Department of Medical Cell Biophysics, University of Twente, Enschede, Netherlands
| | - G Jenster
- Department of Urology, Erasmus University Medical Center, Rotterdam, Netherlands
| | - S Le Gac
- Applied Microfluidics for Bioengineering Research, University of Twente, Enschede, Netherlands
| | - W Lee
- Optical Sciences Group, Department of Science and Technology, University of Twente, Enschede, Netherlands
| | - T G van Leeuwen
- Vesicle Observation Center, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.,Biomedical Engineering and Physics, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | - G B Loozen
- Department of Imaging Physics, Delft University of Technology, Delft, Netherlands
| | - A Nanou
- Department of Medical Cell Biophysics, University of Twente, Enschede, Netherlands
| | - R Nieuwland
- Laboratory of Experimental Clinical Chemistry, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.,Vesicle Observation Center, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | - H L Offerhaus
- Optical Sciences Group, Department of Science and Technology, University of Twente, Enschede, Netherlands
| | - C Otto
- Department of Medical Cell Biophysics, University of Twente, Enschede, Netherlands
| | - D M Pegtel
- Department of Pathology, Amsterdam UMC, VU University Amsterdam, Amsterdam, Netherlands
| | - M C Piontek
- Molecular Biophysics, Zernike Institute, University of Groningen, Groningen, Netherlands
| | - E van der Pol
- Laboratory of Experimental Clinical Chemistry, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.,Vesicle Observation Center, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.,Biomedical Engineering and Physics, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | - L de Rond
- Laboratory of Experimental Clinical Chemistry, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.,Vesicle Observation Center, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.,Biomedical Engineering and Physics, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | - W H Roos
- Molecular Biophysics, Zernike Institute, University of Groningen, Groningen, Netherlands
| | - R B M Schasfoort
- Department of Medical Cell Biophysics, University of Twente, Enschede, Netherlands
| | - M H M Wauben
- Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands
| | - H Zuilhof
- Laboratory of Organic Chemistry, Wageningen University, Wageningen, Netherlands.,School of Pharmaceutical Sciences and Technology, Tianjin University, Tianjin, China
| | - L W M M Terstappen
- Department of Medical Cell Biophysics, University of Twente, Enschede, Netherlands
| |
Collapse
|
3
|
de Jong TD, Vosslamber S, Mantel E, de Ridder S, Wesseling JG, Kraan TCTMDP, Leurs C, Hegen H, Deisenhammer F, Killestein J, Lundberg IE, Vencovsky J, Nurmohamed MT, van Schaardenburg D, Bultink IEM, Voskuyl AE, Pegtel DM, van der Laken CJ, Bijlsma JW, Verweij CL. A6.12 Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-209124.124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
5
|
Pegtel DM, Peferoen L, Amor S. Extracellular vesicles as modulators of cell-to-cell communication in the healthy and diseased brain. Philos Trans R Soc Lond B Biol Sci 2015; 369:rstb.2013.0516. [PMID: 25135977 DOI: 10.1098/rstb.2013.0516] [Citation(s) in RCA: 154] [Impact Index Per Article: 17.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Homeostasis relies heavily on effective cell-to-cell communication. In the central nervous system (CNS), probably more so than in other organs, such communication is crucial to support and protect neurons especially during ageing, as well as to control inflammation, remove debris and infectious agents. Emerging evidence indicates that extracellular vesicles (EVs) including endosome-derived exosomes and fragments of the cellular plasma membrane play a key role in intercellular communication by transporting messenger RNA, microRNA (miRNA) and proteins. In neurodegenerative diseases, secreted vesicles not only remove misfolded proteins, but also transfer aggregated proteins and prions and are thus thought to perpetuate diseases by 'infecting' neighbouring cells with these pathogenic proteins. Conversely, in other CNS disorders signals from stressed cells may help control inflammation and inhibit degeneration. EVs may also reflect the status of the CNS and are present in the cerebrospinal fluid indicating that exosomes may act as biomarkers of disease. That extracellular RNA and in particular miRNA, can be transferred by EV also indicates that these vesicles could be used as carriers to specifically target the CNS to deliver immune modulatory drugs, neuroprotective agents and anti-cancer drugs. Here, we discuss the recent evidence indicating the potential role of exosomes in neurological disorders and how knowledge of their biology may enable a Trojan-horse approach to deliver drugs into the CNS and treat neurodegenerative and other disorders of the CNS.
Collapse
Affiliation(s)
- D M Pegtel
- Exosomes Research Group, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
| | - L Peferoen
- Neuropathology, Department of Pathology, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
| | - S Amor
- Neuropathology, Department of Pathology, VU University Medical Center, 1007 MB Amsterdam, The Netherlands Neuroimmunology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK
| |
Collapse
|